Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2011. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) under the 2009 Deferred Annual Bonus Plan (DABP). Specifically, it details the granting of Post-Tax Awards (Co-Investment Shares) and Matching Awards to eligible executives for the 2010 bonus year, effective March 4, 2011.
Key Financial Metrics and Plan Parameters
The filing does not report consolidated revenue, profit, cash flow, or debt metrics for the company. Instead, it outlines specific financial thresholds tied to executive compensation vesting:
- Adjusted Free Cash Flow Thresholds: Vesting for this performance measure ranges from 25% at £16.15 billion to 100% at £19.15 billion. No vesting occurs below £16.15 billion.
- Share Price: Co-Investment Shares were acquired at an American Depositary Share (ADS) price of US$38.28 on March 4, 2011.
- Performance Period: The awards are subject to a three-year performance period from January 1, 2011, to December 31, 2013.
Material Changes and Plan Structure
The filing details the structure of the DABP Matching Award, which is equally weighted across four strategic performance measures (25% each):
- Total Shareholder Return (TSR): Relative performance against a comparator group of 10 global pharmaceutical companies. Vesting is 0% below median, 30% at median, and up to 100% for top-tier performance.
- Adjusted Free Cash Flow: Based on operating profit adjusted for material factors like exchange rates and legal settlements.
- R&D New Product Measure: Based on New Product Sales (NPS) targets. Specific targets are withheld due to commercial sensitivity.
- Business Diversification: Focuses on revenue targets for Vaccines, Dermatology, Consumer Healthcare, Emerging Markets, and Japan. Specific targets are withheld due to commercial sensitivity.
Two individuals, Ms. D. Connelly and Mr. W. Louv, elected to participate in the Post-Tax basis of the plan. Ms. Connelly acquired 796 ADSs, and Mr. Louv acquired 2,090 ADSs as Co-Investment Shares.
Guidance, Risks, and Contingencies
Management Commentary and Risks:
- Commercial Sensitivity: The Remuneration Committee has decided not to publish specific targets for the R&D new product and business diversification measures at the time of grant. These will be disclosed only at the end of the performance period.
- Vesting Contingencies: All awards are conditional. If performance thresholds are not met, the awards will lapse. Dividends accrue on Matching shares but only vest to the extent the shares themselves vest.
- Regulatory Compliance: The notification is made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the final vesting outcomes for the 2011-2013 performance period, particularly regarding the undisclosed R&D and diversification targets.
- Monitor GSK's Adjusted Free Cash Flow performance against the £16.15 billion to £19.15 billion vesting thresholds.
- Track GSK's Total Shareholder Return (TSR) relative to the specified comparator group (Abbott, AstraZeneca, BMS, Eli Lilly, J&J, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis).
- Note that this filing is a transaction notification and does not contain audited financial statements or operational results for the period.